Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 22Head and Neck Neoplasms 21Rectal Neoplasms 17Colonic Neoplasms 15Neoplasm Metastasis 13Neoplasms 12Carcinoma, Squamous Cell 10Carcinoma, Non-Small-Cell Lung 10Recurrence 5Pancreatic Neoplasms 5Esophageal Neoplasms 4Mouth Neoplasms 3Lung Neoplasms 3Laryngeal Neoplasms 3Laryngeal Diseases 3Breast Neoplasms 3Tongue Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pharyngeal Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms, Squamous Cell 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Glioblastoma 2Colorectal Cancer Metastatic 2Adenocarcinoma of Lung 2Adenocarcinoma Of Esophagus 2

Interventions

Irinotecan 3alectinib 1Leucovorin 1KRN-330 1Fluorouracil 1Cetuximab 1Bevacizumab 1Ascorbic Acid 1ABT-165 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Intestinal Neoplasms × Cetuximab × Clear all
NCT01134666 2017-06-09

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Merck KGaA, Darmstadt, Germany

Terminated
165 enrolled
Gastrointestinal

Intestinal Neoplasms, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡